101 related articles for article (PubMed ID: 12582017)
1. BRCA1 wild-type allele modifies risk of ovarian cancer in carriers of BRCA1 germ-line mutations.
Ginolhac SM; Gad S; Corbex M; Bressac-De-Paillerets B; Chompret A; Bignon YJ; Peyrat JP; Fournier J; Lasset C; Giraud S; Muller D; Fricker JP; Hardouin A; Berthet P; Maugard C; Nogues C; Lidereau R; Longy M; Olschwang S; Toulas C; Guimbaud R; Yannoukakos D; Szabo C; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Goldgar D; Stoppa-Lyonnet D; Lenoir GM; Sinilnikova OM
Cancer Epidemiol Biomarkers Prev; 2003 Feb; 12(2):90-5. PubMed ID: 12582017
[TBL] [Abstract][Full Text] [Related]
2. Functional variant of KLOTHO: a breast cancer risk modifier among BRCA1 mutation carriers of Ashkenazi origin.
Wolf I; Laitman Y; Rubinek T; Abramovitz L; Novikov I; Beeri R; Kuro-O M; Koeffler HP; Catane R; Freedman LS; Levy-Lahad E; Karlan BY; Friedman E; Kaufman B
Oncogene; 2010 Jan; 29(1):26-33. PubMed ID: 19802015
[TBL] [Abstract][Full Text] [Related]
3. The RAD51 135 G>C polymorphism modifies breast cancer and ovarian cancer risk in Polish BRCA1 mutation carriers.
Jakubowska A; Gronwald J; Menkiszak J; Górski B; Huzarski T; Byrski T; Edler L; Lubiñski J; Scott RJ; Hamann U
Cancer Epidemiol Biomarkers Prev; 2007 Feb; 16(2):270-5. PubMed ID: 17301259
[TBL] [Abstract][Full Text] [Related]
4. Common BRCA2 variants and modification of breast and ovarian cancer risk in BRCA1 mutation carriers.
Hughes DJ; Ginolhac SM; Coupier I; Corbex M; Bressac-de-Paillerets B; Chompret A; Bignon YJ; Uhrhammer N; Lasset C; Giraud S; Hardouin A; Berthet P; Peyrat JP; Fournier J; Nogues C; Lidereau R; Muller D; Fricker JP; Longy M; Toulas C; Guimbaud R; Maugard C; Olschwang S; Yannoukakos D; Durocher F; Moisan AM; Simard J; Mazoyer S; Lynch HT; Szabo C; Lenoir GM; Goldgar DE; Stoppa-Lyonnet D; Sinilnikova OM
Cancer Epidemiol Biomarkers Prev; 2005 Jan; 14(1):265-7. PubMed ID: 15668505
[TBL] [Abstract][Full Text] [Related]
5. Germline BRCA1 mutations and loss of the wild-type allele in tumors from families with early onset breast and ovarian cancer.
Merajver SD; Frank TS; Xu J; Pham TM; Calzone KA; Bennett-Baker P; Chamberlain J; Boyd J; Garber JE; Collins FS
Clin Cancer Res; 1995 May; 1(5):539-44. PubMed ID: 9816013
[TBL] [Abstract][Full Text] [Related]
6. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
7. Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus.
Phelan CM; Rebbeck TR; Weber BL; Devilee P; Ruttledge MH; Lynch HT; Lenoir GM; Stratton MR; Easton DF; Ponder BA; Cannon-Albright L; Larsson C; Goldgar DE; Narod SA
Nat Genet; 1996 Mar; 12(3):309-11. PubMed ID: 8589723
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
9. Influence of selected lifestyle factors on breast and ovarian cancer risk in BRCA1 mutation carriers from Poland.
Gronwald J; Byrski T; Huzarski T; Cybulski C; Sun P; Tulman A; Narod SA; Lubinski J
Breast Cancer Res Treat; 2006 Jan; 95(2):105-9. PubMed ID: 16261399
[TBL] [Abstract][Full Text] [Related]
10. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
[TBL] [Abstract][Full Text] [Related]
11. Penetrances of breast and ovarian cancer in a large series of families tested for BRCA1/2 mutations.
Marroni F; Aretini P; D'Andrea E; Caligo MA; Cortesi L; Viel A; Ricevuto E; Montagna M; Cipollini G; Federico M; Santarosa M; Marchetti P; Bailey-Wilson JE; Bevilacqua G; Parmigiani G; Presciuttini S
Eur J Hum Genet; 2004 Nov; 12(11):899-906. PubMed ID: 15340362
[TBL] [Abstract][Full Text] [Related]
12. Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers.
Pepe C; Guidugli L; Sensi E; Aretini P; D'Andrea E; Montagna M; Manoukian S; Ottini L; Radice P; Viel A; Bevilacqua G; Caligo MA
Breast Cancer Res Treat; 2007 May; 103(1):29-36. PubMed ID: 17151928
[TBL] [Abstract][Full Text] [Related]
13. [Mutational analysis of breast/ovarian cancer hereditary predisposition gene BRCA1 in Tunisian women].
Mestiri S; Monastiri K; Ben Ahmed S; Bouaouina N; Presneau N; Bignon YJ; Khairi H; Chouchane L
Arch Inst Pasteur Tunis; 2000; 77(1-4):11-5. PubMed ID: 14658222
[TBL] [Abstract][Full Text] [Related]
14. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers.
Kotsopoulos J; Ghadirian P; El-Sohemy A; Lynch HT; Snyder C; Daly M; Domchek S; Randall S; Karlan B; Zhang P; Zhang S; Sun P; Narod SA
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):912-6. PubMed ID: 17507615
[TBL] [Abstract][Full Text] [Related]
15. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
[TBL] [Abstract][Full Text] [Related]
16. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
King MC; Marks JH; Mandell JB;
Science; 2003 Oct; 302(5645):643-6. PubMed ID: 14576434
[TBL] [Abstract][Full Text] [Related]
17. Younger birth cohort correlates with higher breast and ovarian cancer risk in European BRCA1 mutation carriers.
Kroiss R; Winkler V; Bikas D; Fleischmann E; Mainau C; Frommlet F; Muhr D; Fuerhauser C; Tea M; Bittner B; Kubista E; Oefner PJ; Bauer P; Wagner TM;
Hum Mutat; 2005 Dec; 26(6):583-9. PubMed ID: 16287141
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.
Wenham RM; Schildkraut JM; McLean K; Calingaert B; Bentley RC; Marks J; Berchuck A
Clin Cancer Res; 2003 Oct; 9(12):4396-403. PubMed ID: 14555511
[TBL] [Abstract][Full Text] [Related]
19. Heterogenic loss of the wild-type BRCA allele in human breast tumorigenesis.
King TA; Li W; Brogi E; Yee CJ; Gemignani ML; Olvera N; Levine DA; Norton L; Robson ME; Offit K; Borgen PI; Boyd J
Ann Surg Oncol; 2007 Sep; 14(9):2510-8. PubMed ID: 17597348
[TBL] [Abstract][Full Text] [Related]
20. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada.
Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Fan I; Tang J; Li S; Zhang S; Shaw PA; Narod SA
J Natl Cancer Inst; 2006 Dec; 98(23):1694-706. PubMed ID: 17148771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
